Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04808323 · ClinicalTrials.gov registry record · Phase 1
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
A Phase 1 study of Rectal Adenocarcinoma, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04808323 is a Phase 1 study of Rectal Adenocarcinoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 22 participants, below the 123-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04808323, a Phase 1 study of Rectal Adenocarcinoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a prospective, open-label, phase I design.
Conditions Studied
Interventions
- DRUG Capecitabine
- DEVICE Initial Dose of Radiation before Dose Escalation
- DEVICE Cohort A: Dose Escalation Radiation
- DEVICE Cohort B: Dose Escalation Radiation
- DEVICE Cohort C: Dose Escalation Radiation
Study Locations (1)
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2029-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04808323
The ClinicalTrials.gov registry entry for NCT04808323 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (82% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT04808323 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04808323 about?
NCT04808323 is a clinical study titled "MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer". This study is a prospective, open-label, phase I design.
What is the current status of trial NCT04808323?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-06-17. Estimated completion is 2029-01-20.
What conditions does trial NCT04808323 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma.
What interventions are being tested in trial NCT04808323?
The interventions under investigation include: Capecitabine (DRUG), Initial Dose of Radiation before Dose Escalation (DEVICE), Cohort A: Dose Escalation Radiation (DEVICE), Cohort B: Dose Escalation Radiation (DEVICE), Cohort C: Dose Escalation Radiation (DEVICE).
Who is sponsoring clinical trial NCT04808323?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04808323 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
RECRUITING · Phase 1
-
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.